The goal of the present study was to elucidate the mechanisms of immunoregulation by which dietary punicic acid (PUA) prevents or ameliorates experimental inflammatory bowel disease (IBD). The expression of PPARg and d, their responsive genes and pro-inflammatory cytokines was assayed in the colonic mucosa. Immune cell-specific PPARg null, PPARd knockout and wild-type mice were treated with PUA and challenged with 2·5 % dextran sodium sulphate (DSS). The prophylactic efficacy of PUA was examined in an IL-10 2/2 model of IBD. The effect of PUA on the regulatory T-cell (Treg) compartment was also examined in mice with experimental IBD. PUA ameliorated spontaneous pan-enteritis in IL-10 2/2 mice and DSS colitis, up-regulated Foxp3 expression in Treg and suppressed TNF-a, but the loss of functional PPARg or d impaired these anti-inflammatory effects. At the cellular level, the macrophage-specific deletion of PPARg caused a complete abrogation of the protective effect of PUA, whereas the deletion of PPARd or intestinal epithelial cell-specific PPARg decreased its anti-inflammatory efficacy. We provide in vivo molecular evidence demonstrating that PUA ameliorates experimental IBD by regulating macrophage and T-cell function through PPARg-and d-dependent mechanisms.
Inflammatory bowel disease (IBD) is a widespread and debilitating illness characterised by the destruction of the gut mucosa by the mucosal immune system (1) . Activation of PPARg has shown efficacy in the prevention or amelioration of experimental IBD (2 -4) . Results of a recent clinical study in ulcerative colitis patients demonstrate that rosiglitazone (Avandiae; GlaxoSmithKline, London, UK), an agonist of PPARg and a Food and Drug Administration-approved drug for treating type 2 diabetes, is also efficacious in the treatment of mild-to-moderately active ulcerative colitis (5) . In spite of its efficacy, rosiglitazone is unlikely to be adopted for treating IBD due to its significant side effects (6, 7) and a
Food and Drug Administration-issued 'black box' warning and subsequent restriction of its use. Thus, there is a need to discover novel dual or pan-agonists of PPAR that exert therapeutic and prophylactic actions against IBD with limited or no adverse side effects.
A safer alternative to rosiglitazone in particular, or the thiazolidinedione class of anti-diabetic drugs in general (i.e. rosiglitazone, ciglitazone, troglitazone and pioglitazone), is conjugated linoleic acid (CLA), a naturally occurring fatty acid that ameliorates IBD through a PPARg-dependent mechanism (3, 8, 9) . The efficacy of CLA against experimental IBD heightened our interest in discovering naturally occurring, orally active agonists of PPAR. In this regard, conjugated linolenic acids such as punicic acid (PUA), catalpic acid and eleostearic acid have demonstrated some promising effects as dual or pan-agonists of PPAR (3, 10, 11) . PUA is naturally found at high concentrations in the seed of Punica granatum (Punicaceae, pomegranate) (12) amounting to 64 -83 % of the pomegranate seed fatty acids (13, 14) . Structurally, PUA is a conjugated octadecatrienoic acid containing c9, t11, c13 double bonds, resembling the c9, t11-CLA isomer -the predominant isomer in milk and beef (15, 16) .
As with thiazolidinedione, PUA ameliorates glucose tolerance and obesity-related inflammation in animal models of obesity and type 2 diabetes by acting as dual PPARa and g agonists (11, 17, 18) with no adverse side effects detected in toxicological studies (19) . At the gastrointestinal tract, PUA inhibits TNF-a-induced neutrophil hyperactivation, protects from experimental colitis (20) and ameliorates inflammation-induced colorectal cancer (21) . While some progress has been made in characterising some of the health effects of PUA, its underlying mechanisms of action are incompletely understood. The present study aims to elucidate the underlying mechanisms by which PUA ameliorates experimental IBD. Particularly, we investigate the role of PPAR as putative molecular targets for the prevention of IBD by PUA.
Experimental methods

Animal procedures
C57BL/6J wild-type mice and IL-10 2/2 mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). Tissuespecific PPARg null mice were generated as described previously (3, 22, 23) . The tail and colonic genotypes of mice were determined by PCR analysis as described previously (3, 24) . PPARg fl/fl; mouse mammary tumour virus (MMTV)-Creþ ; IL-10 2/2 double knockout (DK) mice were generated by breeding IL-10 2/2 mice and tissue-specific PPARg null mice expressing the MMTV-Cre recombinase in epithelial and haematopoietic cells. PPARd null mice were backcrossed nine times to a C57BL/6J background and genotyped as described previously (25) . We also utilised Villin-Cre mice lacking PPARg in intestinal epithelial cells (IEC) (26, 27) , CD4-Cre mice lacking PPARg in T-cells (28) and Lysozyme M-Cre mice lacking PPARg in macrophages and neutrophils (29, 30) . All mouse strains were bred under a C57BL/6J background. While we attempted to generate PPARd; IL-10 2/2 DK mice, we were not successful due to increased embryonic mortality of mice lacking both PPARd and IL-10. Mice were maintained at the experimental facilities at Virginia Polytechnic Institute and State University. All experimental protocols were approved by the Institutional Animal Care and Use Committee.
Dietary treatments and development of experimental colitis
Mice were fed purified diets for 6 weeks that represented a modification of the AIN-93G diet (Table 1) commonly used for the growth, pregnancy and lactational phases of mice (31) . The optimal doses of PUA included in these diets were the result of time course and dose titration studies designed to elucidate the optimal anti-inflammatory efficacy of PUA performed previously (data not shown). Diets were prepared on a weekly basis, and feed was replaced on a daily basis to minimise fatty acid oxidation. Stock fatty acid solutions, e.g. pomegranate seed oil, were nitrogen-purged every time that the bottles were opened. The fatty acid profile of pomegranate seed oil was determined by NMR as described previously (12) and shown to contain over 71 % PUA. For studies using
IL-10
2/2 mice, breeder pairs were maintained in specific pathogen-free conditions, and pups were transferred into a conventional environment at weaning ( (3) .
Assessment of colitis
Mice were weighed on a daily basis and examined for clinical signs of disease associated with colitis (i.e. perianal soiling, rectal bleeding, rectal prolapses, diarrhoea and piloerection) by blinded observers. Disease activity indices were calculated using a modification of a previously published compounded clinical score (3, 32) . Briefly, disease activity index consisted of a scoring for diarrhoea and lethargy (0-3), whereas rectal bleeding consisted of a visual observation of blood in faeces and the perianal area (0 -4). Results from preliminary studies demonstrated a high correlation between the results of faecal blood by Hemoccult and visual observations performed by experienced veterinarians. Mice in the DSS study were euthanised by CO 2 narcosis followed by secondary thoracotomy on day 7 of the DSS challenge.
Histopathology
Segments of the colon (3 cm of the anatomic middle of the colon) were fixed in 10 % buffered neutral formalin, later embedded in paraffin, and then sectioned (6 mm) and stained with haematoxylin and eosin for histological examination. Tissue slides were examined as described previously (3, 33, 34) . Briefly, colons were graded with a compounded histological score including the extent of (1) crypt damage, (2) regeneration, (3) metaplasia/hyperplasia, (4) lamina proprial vascular changes, (5) submucosal changes and (6) presence of inflammatory infiltrates. The sections were graded with a range from 0 to 4 for each of the previous categories, and data were analysed as a normalised compounded score. We show the colonic results because the colonic lesions are common in the IL-10 2/2 and DSS colitis models. The ileal lesions can only be found in the IL-10 2/2 model but not in the DSS model, which is colon-specific.
Quantitative real-time RT-PCR from the colon Total RNA was isolated from colonic samples using the RNeasy isolation kit (Qiagen, Valencia, CA, USA) to examine the expression of the three PPAR isoforms and PPAR-responsive genes. The PCR primer pairs for the genes of interest were designed based on previously published sequences (GenBank) using the Oligo 6 primer design software (Molecular Biology Insights, Cascade, CO, USA), and real-time RT-PCR was performed as described previously (3, 9) . Briefly, total RNA was isolated from the whole colon of mice using the RNA isolation MiniKit (Qiagen) according to the manufacturer's instructions. All RNA samples were checked for quality and quantity on the Agilent 2100 BioAnalyser system (Agilent Technologies, Palo Alto, CA, USA). Total RNA (1 mg) from each sample was used to generate a complementary DNA (cDNA) template using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The total reaction volume was 20 ml. The reaction was incubated in a Tetrad thermocycler (MJ Research, Waltham, MA, USA) as follows: 5 min at 258C, 30 min at 428C, 5 min at 858C, hold at 48C. cDNA products were diluted 1:10 in diethylpyrocarbonate-treated water. Controls were also performed with no RNA template (no template) and omitting the RT enzyme (no RT).
The PCR primer pairs were designed based on previously published sequences (GenBank) using the Oligo 6 primer design software (Molecular Biology Insights). The PCR primer pair sequences, annealing temperatures, accession numbers and PCR product lengths are outlined in Table S1 of the supplementary material (available online at http:// www.journals.cambridge.org/bjn.org). PCR was performed on cDNA using Taq DNA Polymerase obtained from Invitrogen (Carlsbad, CA, USA) and using previously described conditions (8, 35) , and each gene amplicon was purified using the MinElute PCR Purification kit (Qiagen). The purified amplicon for each gene was quantified on an agarose gel and also with the GeneQuant Pro spectrophotometer (Amersham Biosciences, Piscataway, NJ, USA). These purified amplicons were further used to optimise the real-time PCR conditions and to generate the standard curves in the real-time PCR assay. Primer concentrations and annealing temperatures were optimised for the iCycler iQ System (Bio-Rad) for each set of primers using the system's gradient protocol. PCR efficiencies were maintained at 100 % for each primer set during optimisation and also during the real-time PCR of sample cDNA.
Statistical analyses
ANOVA was used to determine the statistical significance of the model: main effects of diet, genotype, time, two-way and three-way interactions when time was a factor. ANOVA was performed using the general linear model procedure of Statistical Analysis Software (SAS Institute, Inc., Cary, NC, USA) as described previously (36) . Data were analysed as factorial arrangements of treatments. The statistical model was
where m is the general mean, genotype i is the main effect of the ith level of the genotypic effect (expression of PPARg by the immune and epithelial cells), diet j is the main effect of the jth level of the dietary effect (PUA v. control), (genotype £ diet) ij is the interaction effect between genotype and diet, and error A is the random error. When the model was significant, the analysis was followed by Scheffe's multiple comparison method. Data are expressed as means with their standard errors of the mean. For analysing the results of the disease activity index over time, we used a threefactor repeated-measures ANOVA. For this analysis, in addition to the main effects of diet and genotype and the two-way interaction between diet and genotype (as shown earlier), the model included the main effect of time, the diet £ time, genotype £ time interactions and the three-factor interaction (diet £ genotype £ time). Statistical significance was assessed at a probability value (P,0·05).
Results
Disease activity indices
No effect of PUA was observed in disease activity indices of wild-type mice ( Fig. 1(A) ). PUA prevented experimental IBD in IL-10 2/2 mice ( Fig. 1(B) ). Even though there were some favourable numerical differences, PUA did not cure IBD in mice that received it after having developed severe clinical signs such as rectal prolapses ( Fig. 1(C) ). The deficiency of PPARg in immune and epithelial cells in PPARg fl/fl; MMTVCreþ ; IL-10 DK mice abrogated the beneficial effect of PUA in experimental IBD (Fig. 1(D) ) even when PUA was administered preventively. Even though we also attempted to generate a line of PPARd; IL-10 DK, we were unable to produce this line due to embryonic mortality associated with this genotype. Thus, we evaluated the role of PPARd in PUA-mediated protection from IBD using a model of DSS colitis.
Intestinal inflammatory lesions
The architecture of colons recovered from IL-10 2/2 P mice administered PUA resembled those of healthy wild-type mice. Specifically, PUA significantly decreased the histological scores, including lymphoplasmacytic infiltration and enlargement of the colonic mucosa of IL-10 2/2 P, but not in IL-10 2/2 T, mice or in PPARg fl/fl; MMTV-Creþ ; IL-10 DK mice (Fig. 2) .
Quantification of colonic gene expression
Quantitative real-time RT-PCR analyses demonstrated that colonic PPARd was significantly up-regulated, and the expression of PPARd-responsive gene angiopoietin-like 4 was numerically increased by PUA (Fig. 3(A) and (B) ). No differences were observed in the colonic expression of PPARa, g or their responsive genes CD36, FABP4 and stearoyl coenzyme A desaturase 1 (data not shown). PUA suppressed the colonic expression of both TNF-a and MCP-1 ( Fig. 3(C) and (D)). PUA significantly up-regulated the colonic expression of keratinocyte growth factor in comparison with control diet-fed mice (0·01 v. 0·005, P,0·02). Kerationocyte growth factor is a growth factor associated with epithelial wound healing.
Effect of cell-specific deficiency of PPARg and d on the ability of punicic acid to prevent or ameliorate dextran sodium sulphate colitis PUA protected wild-type mice from experimental IBD, but its beneficial effects in disease activity and colonic lesions were abrogated in PPARd null mice (Fig. 4) and significantly impaired in IEC-specific (Villin-Cre) (Fig. 5 ) and macrophage-specific (Lysozyme M-Cre) PPARg null mice (Fig. 6 ), suggesting that PPARg and d in immune and epithelial cells are required for PUA-mediated protection from experimental IBD. The highest disease activity was observed in Lysozyme M-Cre mice, regardless of the diet (Fig. 6) , indicating that the deficiency of PPARg in macrophages is a particularly important contributor to the immunopathogenesis of IBD, as shown previously (29) . Flow cytometric analyses of T-cell subsets in blood and mesenteric lymph nodes (MLN) demonstrated that PUA increased the percentages of regulatory T-cells in the blood of wild-type mice but not in mice lacking PPARg or d in immune or epithelial cells (Fig. 7) .
Discussion
Nutritional influences can target the main components of mucosal homeostasis during IBD and contribute to either attenuating or accentuating the onset of disease (37, 38) . Both fatty acid composition of the diet and total amount of dietary fat (39 -41) define the variables of lipid nutrition that influence health and disease. For instance, mixed results are available on the modulation of intestinal inflammation by n-3 PUFA, although CLA has shown anti-inflammatory efficacy more consistently, primarily by targeting PPAR (42) . At the molecular level, PPAR represent important targets for the actions of dietary lipid (43) and major contributors to the maintenance of intestinal homeostasis. In this regard, PPARg gene therapy enhances PPARg mRNA expression, resulting in dramatic therapeutic benefits in the DSS colitis model (2) . CLA induced colonic PPARg expression and provided protection against the disease in a pig model of bacterial-induced colitis (8) , as well as in mouse and pig models of DSS colitis (3, 9) . The present study investigates the possibility of a PPAR-dependent mechanism underlying the anti-inflammatory efficacy of PUA against experimental IBD. PPARg and d are recognised as central inhibitors of intestinal inflammation in DSS colitis (44 -47) . In addition, activation of PPARg by rosiglitazone ameliorated spontaneous panenteritis caused by the deficiency of IL-10 (4) . In the present study, we provide evidence that preventive administration of PUA ameliorated IBD in two mouse models of IBD. However, PUA was not effective in IL-10 2/2 mice with established severe inflammatory lesions (i.e. rectal prolapses) and PPARg; IL-10 DK mice. The latter finding suggests that the anti-inflammatory efficacy of PUA depends on the expression of functional PPARg in immune and epithelial cells. Interestingly, colonic expression of PPARd and its responsive gene angiopoietin-like 4 was up-regulated in IL-10 2/2 mice that received PUA preventively. These in vivo findings were in line with increased PPARd reporter activity induced by PUA in vitro in IEC and macrophages. As CLA (9) , PUA up-regulated colonic kerationocyte growth factor levels in the present study. Since PPARd plays an important role in re-epithelialisation in mouse epidermis (48) , the up-regulated colonic keratinocyte growth factor may be indicative of a PPARd-mediated re-epithelialisation of the gut mucosa. In contrast to PPARd and its responsive genes, colonic levels of PPARg, a and their responsive genes remained unchanged. Nonetheless, since PUA transactivates PPARg in 3T3-L1 preadipocytes (11) and given the abrogation of the effect of PUA that we observed in PPARg; IL-10 DK mice, this isoform was also investigated as a putative target for PUA. PPARg suppresses inflammation by antagonising NF-kB, STAT and AP-1 (49) , favouring the nucleocytoplasmic shuttling of the activated p65 subunit of NF-kB (50) , and SUMOylation of PPARg results in a stable repressed state of NF-kB (51) . Thus, the down-regulation of TNF-a in colons of PUA-fed mice and M1 macrophages treated with PUA is consistent with the PPARg-dependent anti-inflammatory effects of this compound.
The selective PPARg agonist rosiglitazone suppressed colonic inflammation even when PPARg was deleted from colonic epithelial cells, suggesting either an epithelial PPARg-independent effect or a possible role for macrophages as a cellular target (26) . In addition, activation of PPARg and d has been shown to suppress M1 classically activated or pro-inflammatory macrophage activation and favour M2 alternatively activated or anti-inflammatory macrophage differentiation (52 -54) .
Moreover, PPARg and d have been shown to exert overlapping anti-inflammatory effects in lipopolysaccharide-stimulated macrophages (55) . Based on this background, to further characterise the putative roles of PPARg and d as targets for PUA, we determined whether the deletion of these genes impaired or abrogated its ability to ameliorate experimental IBD. Our data demonstrate that both PPARg and d are required for PUA-mediated protection from DSS colitis. Additionally, PPARg was also required for PUA-mediated protection from IL-10-induced pan-enteritis since the preventive effect of PUA was abrogated in PPARg; IL-10 DK mice. However, we could not test the role of PPARd in spontaneous pan-enteritis in IL-10 knockout mice since PPARd; IL-10 DK mice did not survive beyond the embryonic stages.
At the cellular level, the deletion of PPARg in macrophages completely abrogated the beneficial effect of PUA, whereas its deletion in IEC or the whole-body deletion of PPARd impaired, but did not completely abrogate, the anti-inflammatory activity of PUA in the gut. Together, these data indicate that PUA ameliorates experimental IBD by down-modulating inflammation in mucosal immune and epithelial cells through PPARg-and d-dependent mechanisms. In support of this assertion, we provide in vitro evidence demonstrating that PUA treatment suppressed the TNF-a-and MCP-1-producing abilities of wild-type M1 classically activated macrophages, but it failed to exert these suppressive effects in PPARg or d null macrophages. Furthermore, PUA intake increased the peripheral blood regulatory T-cell compartment in wild-type mice but not in PPARg or d null mouse strains. These findings are in line with a PPARg-dependent up-regulation of Foxp3 in regulatory T-cells treated with PUA (data not shown). Of note, regulatory T-cells mediate protection from experimental colitis through PPARg-dependent mechanisms (28, 34) . Since colonic PPARg was required for some of the anti-inflammatory effects of PUA in vivo, but it did not activate PPARg reporter activity directly, further studies are required to determine whether IEC and/or immune cells produced endogenous PPARg agonists in response to PUA-mediated activation of PPARd. In conclusion, PUA prevented experimental IBD through a mechanism requiring adequate expression of PPARg and d in immune cells and IEC in the colonic mucosa.
